TITLE

Identifying and Attaining LDL-C Goals: Mission Accomplished? Next Target: New Therapeutic Options to Raise HDL-C Levels

AUTHOR(S)

Athyros, Vasilios G.; Mikhailidis, Dimitri P.; Kakafika, Anna I.; Karagiannis, Asterios; Hatzitolios, Apostolos; Tziomalos, Konstantinos; Ganotakis, Emmanuel S.; Liberopoulos, Evangelos N.; Elisaf, Moses

PUB. DATE

March 2007

SOURCE

Current Drug Targets;Mar2007, Vol. 8 Issue 3, p483

SOURCE TYPE

Academic Journal

DOC. TYPE

Article

ABSTRACT

Currently, low density lipoprotein cholesterol (LDL-C) levels are the main, if not the only, lipid target in the effort to reduce cardiovascular disease (CVD) morbidity and mortality. Several primary and secondary CVD prevention trials with statins shaped current guidelines and provided detailed targets across a range of CVD risk categories. These targets can be attained using effective statins or combination therapy. However, the net benefit in CVD risk reduction may be improved if we address other lipid risk factors. High density lipoprotein cholesterol (HDL-C) emerges from epidemiological studies as the most promising target. This review links the increase in HDL-C levels with clinical benefit from �old� (e.g. sustained release niacin) and new treatment options. Synthetically produced recombined apolipoprotein A-I Milano administered intravenously seems to have a marked effect in reducing the atheroma burden. The anti-cholesterol ester transfer protein (CETP) vaccine (CETi-1) produces auto-antibodies against CETP thus increasing the cholesterol ester content in HDL particles. CETP inhibitors (e.g. JTT-705 and torcetrapib) seem to be the most promising regimen to increase HDL-C levels. Torcetrapib (already in phase IIIa studies) can substantially increase HDL-C levels (up to 106%), alone or in combination with atorvastatin. HDL-C strategies, in combination with effective statins, are a new drug target aimed at a further reduction in CVD morbidity and mortality compared with statin monotherapy.

ACCESSION #

24195533

Tags: LOW density lipoproteins;  CARDIOVASCULAR system -- Diseases;  STATINS (Cardiovascular agents);  ATHEROSCLEROTIC plaque;  APOLIPOPROTEINS;  HIGH density lipoproteins

 

Related Articles

• Statin benefits keep on growing.  // Cortlandt Forum;Mar2007, Vol. 20 Issue 3, p13 

  The article presents two studies which identify the substantial benefits of statins. In the first, researchers discovered that when statins decreased low density lipoproteins (LDL) and raised high density lipoproteins (HDL) by at least 7.5 percent patients experienced decrease in atheroma...

• Statin therapy reduces first event severity.  // Geriatrics;May2006, Vol. 61 Issue 5, p9 

  Discusses research being done on the role of statins in reversing plaque progression and reducing the chances of a more serious initial presentation of coronary symptoms. Reference to a study by Alan Go et al in a 2006 issue of "Annals of Internal Medicine"; Effects of statins on lowering low...

• HDL and LDL cholesterol predict cardiovascular risk independently.  // Active Living;Jan2008, Vol. 17 Issue 1, p29 

  The article provides information on the risk of high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol. Physicians treating patients with heart disease tend to concentrate most of their efforts on using statins to bring down serum concentrations of LDL cholesterol....

• Add a fibrate to a statin? Lounsbery, Jody; Prasad, Shailendra; Rowland, Kate // Journal of Family Practice;Oct2010, Vol. 59 Issue 10, p582 

  The article explores the addition fenofibrate in a 60-year-old man with cardiovascular disease and diabetes. The patient is on statin therapy and his fasting lipid panel shows a low-density lipoprotein and a high-density lipoprotein (HDL). It is considered that adding a fibrate to statin therapy...

• Torcetrapib: A new strategy to raise HDL cholesterol levels. Bhardwaj, R.; Bhardwaj, P. // Indian Journal of Pharmacology;Feb2005, Vol. 37 Issue 1, p46 

  The article presents a new strategy to raise high-density lipoprotein (HDL) cholesterol levels. HDL cholesterol constitutes a common lipid abnormality in coronary heart disease patients. Agents that increase the HDL cholesterol level are inhibitors of cholesteryl ester transfer protein (CETP)...

• The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis? Rader, Daniel J; Tall, Alan R // Nature Medicine;Sep2012, Vol. 18 Issue 9, p1344 

  The article offers information regarding high-density lipoproteins (HDLs), which can remove cholesterol from the circulation and can be used as cardioprotective. It mentions the formation of plaques in arteries due to lowdensity lipoproteins (LDLs) leading to cardiovascular disease risk and...

• Non — HDL Cholesterol May Be Stronger Target for Statin Therapy.  // Neurology Reviews;May2012, Vol. 20 Issue 5, p1 

  The article focuses on the research study which shows the associations of the levels of non-high-density lipoprotein cholesterol (non-HDL-C) and low-density lipoprotein cholesterol (LDL-C) of of apolopoprotein B (apoB) to cardiovascular events, According to the study, there is no difference in...

• New targets and developments in lipoproteins control. Norata, Giuseppe Danilo // Research Reports in Clinical Cardiology;May2013, Vol. 4, p77 

  Statins provide a very effective approach in reducing plasma cholesterol levels and cardiovascular risk. However, the proportion of patients who fail to achieve desirable plasma lipid levels ranges from 16%-53%, worldwide. This percentage reaches up to 80% in patients with familial...

• Management of Hypertriglyceridemia. Oh, Robert C.; Lanier, J. Brian // American Family Physician;5/1/2007, Vol. 75 Issue 9, p1365 

  Hypertriglyceridemia is associated with an increased risk of cardiovascular events and acute pancreatitis. Along with lowering low-density lipoprotein cholesterol levels and raising high-density lipoprotein cholesterol levels, lowering triglyceride levels in high-risk patients (e.g., those with...

Read the Article